Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Aug 4;217(10):e20191515. doi: 10.1084/jem.20191515

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Varga et al.

This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms/). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 International license, as described at https://creativecommons.org/licenses/by-nc-sa/4.0/).

PMC Copyright notice

Figure 7. — High NOTCH3 expression correlates with CRC progression and CMS4 subtype in CRC patients. (a) Kaplan–Meier survival curve of CRC patients with NOTCH3 under- or overexpression. Data were generated by using the cBioPortal and TCGA RNA sequencing V2 dataset with a z-score threshold of ±1. Underexpression was considered for expression values smaller than one SD below the mean (n = 327), overexpression was considered for expression values greater than one SD above the mean (n = 46). Curve comparison was performed with log-rank (Mantel–Cox) test. (b–e) NOTCH3 normalized expression in CRC patients according to the tumor stage (T1–T4; b), LVI (c), lymphatic metastasis (N0–N2; d), and distant metastasis (M0–M1; e). Data were generated by using the cBioPortal and TCGA RNA sequencing V2 dataset with a z-score threshold of ±1. Data are mean ± SD, n = 374. *, P < 0.05; **, P < 0.01; ***, P < 0.001 by t test or one-way ANOVA followed by Tukey’s multiple comparison test. (f) Representative image of N3ICD immunohistochemistry (IHC) in human CRC. Scale bar = 100 µm. (g) Kaplan–Meier survival curve of CRC patients with NOTCH1 under- or overexpression. Data were generated by using the cBioPortal and TCGA RNA sequencing V2 dataset with a z-score threshold of ±1. Underexpression was considered for expression values smaller than one SD below the mean (n = 320), overexpression was considered for expression values greater than one SD above the mean (n = 52). Curve comparison was performed with log-rank (Mantel–Cox) test. (h–k) NOTCH1 normalized expression in CRC patients according to the tumor stage (T1–T4; h), LVI (i), lymphatic metastasis (N0–N2; j), and distant metastasis (M0–M1; k). Data were generated by using the cBioPortal and TCGA RNA sequencing V2 dataset with a z-score threshold of ±1. Data are mean ± SD; n = 374. Not significant by t test or one-way ANOVA followed by Tukey’s multiple comparison test. (l) NOTCH3 expression in the indicated human CRC datasets according to the CMS category. Data are mean ± SD; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001 by one-way ANOVA followed by Dunnett’s multiple comparison test. (m) NOTCH1 expression in the indicated human CRC datasets according to the CMS category. Data are mean ± SD; *, P < 0.05; **, P ≤ 0.01; ***, P ≤ 0.001; ****, P ≤ 0.0001 by one-way ANOVA followed by Dunnett’s multiple comparison test.